Is Regorafenib on the market?

Regorafenib (Regorafenib) is an oral inhibitor of multiple kinases used to treat metastatic colorectal cancer (CRC), advanced gastrointestinal stromal tumor (GIST) and hepatocellular carcinoma (HCC). The U.S. Food and Drug Administration (FDA) approved Swiss in September 2012 Gorfenib was launched and sold under the trade name Stivarga, and in April 2017, the approved use of regorafenib was expanded to treat hepatocellular carcinoma.

Regofenib has been proven to increase the overall survival of patients with metastatic colorectal cancer, and was approved by the US FDA in September 2012. In February 2013, the US FDA expanded its approved use to treat patients with advanced gastrointestinal stromal tumors that cannot be surgically removed and no longer respond to other FDA-approved treatments. In a clinical study of 199 patients, patients who received regorafenib experienced tumor growth delays (progression-free survival) that were 3.9 months longer on average than those who received placebo. In 2018, the United States approved the use of regorafenib in patients with advanced hepatocellular carcinoma who were previously treated with sorafenib.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).